Thomas E. Boyd
Impact in
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research
- Pathology and Forensic Medicine top 0.5%
- Lymphoma Diagnosis and Treatment
Papers in
- Genetics 39
- Chronic Lymphocytic Leukemia Research 34
-
- Lymphoma Diagnosis and Treatment 20
- Co-authors
- Nathan Fowler (19 shared papers)Jeff P. Sharman (22 shared papers)Richard R. Furman (15 shared papers)Kathryn S. Kolibaba (7 shared papers)Ranjana H. Advani (6 shared papers)Sonali M. Smith (5 shared papers)Ahmed Hamdy (4 shared papers)Barbara Grant (3 shared papers)
- Journals
- Blood (23 papers)Journal of Clinical Oncology (15 papers)Investigational New Drugs (2 papers)Leukemia Research (2 papers)The Oncologist (2 papers)
- Partner nations
- United StatesUnited KingdomFrance
In The Last Decade
Thomas E. Boyd
55 papers receiving 2.4k citations
Thomas E. Boyd's Hit Papers
Peers
Comparison fields: 5 of 66
- Genetics 1.3k
- Pathology and Forensic Medicine 1.0k
- Hematology 445
- Oncology 625
- Immunology 490
Countries citing papers authored by Thomas E. Boyd
This map shows the geographic impact of Thomas E. Boyd's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas E. Boyd with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas E. Boyd more than expected).
Fields of papers citing papers by Thomas E. Boyd
This network shows the impact of papers produced by Thomas E. Boyd. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas E. Boyd. The network helps show where Thomas E. Boyd may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas E. Boyd, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 56 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies Hit paper breakdown → | 2012 | 856 |
| 2 | 2007 | 218 | |
| 3 | 2015 | 190 | |
| 4 | 2009 | 126 | |
| 5 | 2009 | 64 | |
| 6 | 2018 | 59 | |
| 7 | 2014 | 59 | |
| 8 | 2013 | 57 | |
| 9 | 2016 | 56 | |
| 10 | 2019 | 55 | |
| 11 | 2017 | 41 | |
| 12 | 2012 | 38 | |
| 13 | 2010 | 36 | |
| 14 | 2015 | 32 | |
| 15 | 2013 | 31 | |
| 16 | 2004 | 30 | |
| 17 | 2012 | 30 | |
| 18 | 2011 | 28 | |
| 19 | 2013 | 27 | |
| 20 | 2013 | 26 |
About Thomas E. Boyd
Thomas E. Boyd is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Hematology and Immunology, having authored 56 papers that have together received 2.4k indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (34 papers), Lymphoma Diagnosis and Treatment (20 papers), Chronic Myeloid Leukemia Treatments (9 papers), Immunodeficiency and Autoimmune Disorders (9 papers), Acute Myeloid Leukemia Research (7 papers), Lung Cancer Treatments and Mutations (7 papers), Acute Lymphoblastic Leukemia research (6 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). The work is most often cited by research in Genetics (1.3k citations), Pathology and Forensic Medicine (1.0k citations), Hematology (445 citations), Oncology (625 citations) and Immunology (490 citations). Thomas E. Boyd has collaborated with scholars based in United States, United Kingdom and France. Frequent co-authors include Nathan Fowler, Jeff P. Sharman, Richard R. Furman, Kathryn S. Kolibaba, Ranjana H. Advani, Sonali M. Smith, Ahmed Hamdy, Barbara Grant, Joseph J. Buggy and Juthamas Sukbuntherng. Their work appears in journals such as Blood, Journal of Clinical Oncology, Investigational New Drugs, Leukemia Research and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.